Alexander Borowsky

Clinical/Research Interests

Alexander Borowsky is a surgical pathologist with expertise in diagnostic breast pathology and interests in molecular oncology and genetically engineered mouse pathology. His research training includes characterization of a fusion oncogene central to the pathogenesis of lymphoma of mucosa-associated lymphoid tissue (MALT). He is a member of the UC Davis Center for Comparative Medicine and Mouse Biology Program.

Title

Associate Professor

Specialty

Pathology and Laboratory Medicine, Cancer

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

Vanderbilt University School of Medicine, Nashville, Tennesse, M.D., 1994
Pomona College, Claremont, California, B.A., 1989

Residency

Vanderbilt Medical Center, Nashville, Tennessee, 1994-96, Anatomic Pathology

Fellowships

Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, 1998-2001, Molecular Oncology
Vanderbilt Medical Center, Nashville , Tennessee, 1996-97, Surgical Pathology

Professional Memberships

American Association for the Advancement of Science
American Association of Cancer Research
Canada-California Cancer Stem Cell Think-Tank
College Of American Pathologists
United States and Canadian Academy of Pathology

Honors and Awards

Stowell-Orbison Prize, awarded to the outstanding paper presented by a pathologist-in-training, US and Canadian Academy of Pathology Mtg, 1997
John Shapiro Award for Excellence in Pathology, Vanderbilt School of Medicine, 1994
School of Medicine Award of Distinction, Vanderbilt School of Medicine, 1994

Select Recent Publications

Kuil J, Buckle T, Oldenburg J, Yuan H, Borowsky AD, Josephson L, van Leeuwen FW. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm. 2011 Dec 5;8(6):2444-53. Epub 2011 Nov 15.

Kuil J, Buckle T, Oldenburg J, Yuan H, Borowsky AD, Josephson L, van Leeuwen FW. Hybrid

UCDAVIS HEALTH SYSTEM

Alexander Borowsky

peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm. 2011 Dec 5;8(6):2444-53. Epub 2011 Nov 15.

Kuil J, Buckle T, Oldenburg J, Yuan H, Borowsky AD, Josephson L, van Leeuwen FW. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm. 2011 Dec 5;8(6):2444-53. Epub 2011 Nov 15.

Kuil J, Buckle T, Oldenburg J, Yuan H, Borowsky AD, Josephson L, van Leeuwen FW. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm. 2011 Dec 5;8(6):2444-53. Epub 2011 Nov 15.

Nguyen DH, Oketch-Rabah HA, Illa-Bochaca I, Geyer FC, Reis-Filho JS, Mao JH, Ravani SA, Zavadil J, Borowsky AD, Jerry DJ, Dunphy KA, Seo JH, Haslam S, Medina D, Barcellos-Hoff MH. Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell. 2011 May 17;19(5):640-51.

Bandhuvula P, Honbo N, Wang GY, Jin ZQ, Fyrst H, Zhang M, Borowsky AD, Dillard L, Karliner JS, Saba JD. S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol. 2011 May;300(5):H1753-61. Epub 2011 Feb 18.

Rygh CB, Qin S, Seo JW, Mahakian LM, Zhang H, Adamson R, Chen JQ, Borowsky AD, Cardiff RD, Reed RK, Curry FR, Ferrara KW. Longitudinal investigation of permeability and distribution of macromolecules in mouse malignant transformation using PET. Clin Cancer Res. 2011 Feb 1;17 (3):550-9. Epub 2010 Nov 24.

de Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, Borowsky AD, Chew HK, Lebrilla CB. High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics. 2011 Jan;10(1):M110.002717. Epub 2010 Nov 19.

Kheirolomoom A, Mahakian LM, Lai CY, Lindfors HA, Seo JW, Paoli EE, Watson KD, Haynam EM, Ingham ES, Xing L, Cheng RH, Borowsky AD, Cardiff RD, Ferrara KW. Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol Pharm. 2010 Dec 6;7(6):1948-58.

Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky

Alexander Borowsky

AD, Chen HW. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010 Nov 15;70(22):9402-12. Epub 2010 Sep 23.

© 2013 UC Regents

UCDAVIS
HEALTH SYSTEM